AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 21683660 — intervention group
Group type: EXPERIMENTAL
Intervention: Blue light therapy (400 lux for 30 minutes per day, Monday through Friday, for 4 weeks)
Number of subjects: 28
Study 21683660 — intervention group
Group type: COMPARATOR
Intervention: Placebo red light therapy (75 lux)
Number of subjects: 28
Study 21683660 — intervention group
Group type: EXPERIMENTAL
Intervention: Blue light therapy
Number of subjects: 28
Study 21683660 — intervention group
Group type: COMPARATOR
Intervention: Placebo red light therapy
Number of subjects: 28
Study 19357997 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5% lidocaine with 0.1 mg.kg(‐1) morphine (Group LM)
Number of subjects: 90
Study 19357997 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5% lidocaine with 1.5 mg.kg(‐1) tramadol (Group LT)
Number of subjects: 90
Study 19357997 — intervention group
Group type: COMPARATOR
Intervention: 0.5% lidocaine (Group L)
Number of subjects: 90
Study 17453361 — intervention group
Group type: EXPERIMENTAL
Intervention: Tamoxifen for 2 or 5 years
Number of subjects: 2738
Study 17453361 — intervention group
Group type: COMPARATOR
Intervention: No adjuvant endocrine therapy
Number of subjects: 2738
Study 15084368 — intervention group
Group type: EXPERIMENTAL
Intervention: Implantable cardioverter defibrillator (ICD)
Number of subjects: 285
Study 15084368 — intervention group
Group type: COMPARATOR
Intervention: Antiarrhythmic drugs (AADs)
Number of subjects: 285
Study 15084368 — intervention group
Group type: EXPERIMENTAL
Intervention: Inducibility at baseline PVS
Number of subjects: 285
Study 15084368 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-inducible patients
Number of subjects: 285
Study 15084368 — intervention group
Group type: EXPERIMENTAL
Intervention: Inducible patients
Number of subjects: 285
Study 12205826 — intervention group
Group type: EXPERIMENTAL
Intervention: Personal stereo
Number of subjects: 1
Study 12205826 — intervention group
Group type: COMPARATOR
Intervention: Control treatment (nonfunctioning hearing aid)
Number of subjects: 1
Study 9793750 — intervention group
Group type: EXPERIMENTAL
Intervention: Home-based rehabilitation
Number of subjects: 0
Study 9793750 — intervention group
Group type: COMPARATOR
Intervention: Hospital-based rehabilitation
Number of subjects: 0
Study 2187945 — intervention group
Group type: EXPERIMENTAL
Intervention: MCT diet (40% of energy as medium chain triglycerides)
Number of subjects: 10
Study 2187945 — intervention group
Group type: COMPARATOR
Intervention: LCT diet (40% of energy as long chain triglycerides, soybean oil)
Number of subjects: 10
Study 791197 — intervention group
Group type: EXPERIMENTAL
Intervention: Deanol (dimethylaminoethanol)
Number of subjects: 20
Study 791197 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 20
Study 30540649 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral iron polysaccharide 150 mg twice daily for 16 weeks
Number of subjects: 98
Study 30540649 — intervention group
Group type: COMPARATOR
Intervention: Matching placebo for 16 weeks
Number of subjects: 98
Study 29210011 — intervention group
Group type: EXPERIMENTAL
Intervention: Um‐PEA 600 mg twice daily
Number of subjects: 11
Study 29210011 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 11
Study 26008654 — intervention group
Group type: COMPARATOR
Intervention: Placebo (Group-C, n=30)
Number of subjects: 90
Study 26008654 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral tramadol 100 mg (Group-T, n=30)
Number of subjects: 90
Study 26008654 — intervention group
Group type: EXPERIMENTAL
Intervention: Famotidine 40 mg (Group-F, n=30)
Number of subjects: 90
Study 23066987 — intervention group
Group type: EXPERIMENTAL
Intervention: Pentagastrin infusion
Number of subjects: 12
Study 23066987 — intervention group
Group type: COMPARATOR
Intervention: Placebo infusion
Number of subjects: 12
Study 21975305 — intervention group
Group type: EXPERIMENTAL
Intervention: eCG (500 IU Folligon®)
Number of subjects: 21
Study 21975305 — intervention group
Group type: EXPERIMENTAL
Intervention: eCG-hCG (500 IU Folligon® + 500 IU Chorulon®)
Number of subjects: 21
Study 21975305 — intervention group
Group type: COMPARATOR
Intervention: Control (no treatment)
Number of subjects: 21
Study 17852302 — intervention group
Group type: EXPERIMENTAL
Intervention: Multidisciplinary treatment (including psychological/cognitive-behavioral components)
Number of subjects: 50
Study 17852302 — intervention group
Group type: COMPARATOR
Intervention: Not applicable (control group of patients who did not start treatment)
Number of subjects: 50
Study 16139783 — intervention group
Group type: EXPERIMENTAL
Intervention: Duration production tasks
Number of subjects: 0
Study 16139783 — intervention group
Group type: EXPERIMENTAL
Intervention: Duration reproduction tasks
Number of subjects: 0
Study 12674391 — intervention group
Group type: EXPERIMENTAL
Intervention: Interactive voice response system
Number of subjects: 0
Study 10929741 — intervention group
Group type: EXPERIMENTAL
Intervention: i.v. heparin (5,000 IU bolus + 1,000 IU/h)
Number of subjects: 18
Study 10929741 — intervention group
Group type: COMPARATOR
Intervention: i.v. 0.9% NaCl (placebo)
Number of subjects: 18
Study 8833417 — intervention group
Group type: EXPERIMENTAL
Intervention: Idazoxan (IDZ)
Number of subjects: 3
Study 1428183 — intervention group
Group type: EXPERIMENTAL
Intervention: Clarithromycin
Number of subjects: 9
Study 1428183 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 9
Study 1428183 — intervention group
Group type: EXPERIMENTAL
Intervention: Clarithromycin (maintenance phase)
Number of subjects: 9
Study 6747977 — intervention group
Group type: EXPERIMENTAL
Intervention: Strep. pneumoniae diagnosed as the cause of pneumonia
Number of subjects: 80
Study 6747977 — intervention group
Group type: EXPERIMENTAL
Intervention: No causative organism demonstrated
Number of subjects: 80
Study 6747977 — intervention group
Group type: EXPERIMENTAL
Intervention: Diagnosis methods for pneumococcal infection
Number of subjects: 80
Study 6747977 — intervention group
Group type: EXPERIMENTAL
Intervention: Bacteraemic cases
Number of subjects: 80
Study 6747977 — intervention group
Group type: EXPERIMENTAL
Intervention: Mortality rate
Number of subjects: 80
Study 6747977 — intervention group
Group type: EXPERIMENTAL
Intervention: Severity of community-acquired pneumococcal pneumonia
Number of subjects: 80
Study 30861061 — intervention group
Group type: EXPERIMENTAL
Intervention: ZTI-01 (6 g q8h for 7 days)
Number of subjects: 465
Study 30861061 — intervention group
Group type: COMPARATOR
Intervention: Piperacillin-tazobactam (4.5 g IV q8h for 7 days)
Number of subjects: 465
Study 27773347 — intervention group
Group type: EXPERIMENTAL
Intervention: Chewed ticagrelor tablets
Number of subjects: 99
Study 27773347 — intervention group
Group type: EXPERIMENTAL
Intervention: Crushed ticagrelor tablets
Number of subjects: 99
Study 27773347 — intervention group
Group type: COMPARATOR
Intervention: Integral ticagrelor tablets
Number of subjects: 99
Study 26373270 — intervention group
Group type: EXPERIMENTAL
Intervention: HMB-FA (free acid form) administered in capsules
Number of subjects: 10
Study 26373270 — intervention group
Group type: EXPERIMENTAL
Intervention: HMB-FA (free acid form) administered in water
Number of subjects: 10
Study 26373270 — intervention group
Group type: COMPARATOR
Intervention: Ca-HMB (calcium salt form) administered in capsules
Number of subjects: 10
Study 26373270 — intervention group
Group type: COMPARATOR
Intervention: Ca-HMB (calcium salt form) administered in water
Number of subjects: 10
Study 24530134 — intervention group
Group type: COMPARATOR
Intervention: Conventional group (daily steroids)
Number of subjects: 19
Study 24530134 — intervention group
Group type: EXPERIMENTAL
Intervention: Pulse group (weekly doses of steroids)
Number of subjects: 19
Study 22955394 — intervention group
Group type: EXPERIMENTAL
Intervention: 36-mm Delta ceramic-on-ceramic (COC) articulation
Number of subjects: 93
Study 22955394 — intervention group
Group type: COMPARATOR
Intervention: common-sized alumina ceramic head on polyethylene liner (COP) articulation
Number of subjects: 93
Study 20621545 — intervention group
Group type: EXPERIMENTAL
Intervention: Specific ultrasound guided exercises
Number of subjects: 109
Study 20621545 — intervention group
Group type: EXPERIMENTAL
Intervention: General exercises
Number of subjects: 109
Study 20621545 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 109
Study 17213498 — intervention group
Group type: EXPERIMENTAL
Intervention: Telemedicine application (electronic health information support system) for 6 weeks post-discharge
Number of subjects: 184
Study 17213498 — intervention group
Group type: COMPARATOR
Intervention: Control group (no telemedicine intervention)
Number of subjects: 184
Study 15882799 — intervention group
Group type: EXPERIMENTAL
Intervention: IVS1‐21G>A polymorphism in GABRA5 gene
Number of subjects: 0
Study 15882799 — intervention group
Group type: EXPERIMENTAL
Intervention: Haplotype IVS1‐21G>A/IVS2‐26A>T
Number of subjects: 0
Study 15882799 — intervention group
Group type: EXPERIMENTAL
Intervention: Haplotype IVS1‐21A/IVS2‐26T
Number of subjects: 0
Study 11922646 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified MAZE operation using intra‐operatively cooled‐tip radiofrequency ablation (group A)
Number of subjects: 30
Study 11922646 — intervention group
Group type: COMPARATOR
Intervention: Mitral valve replacement alone (group B)
Number of subjects: 30
Study 9444412 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral fleroxacin 400 mg once a day for 7 days
Number of subjects: 95
Study 9444412 — intervention group
Group type: COMPARATOR
Intervention: Cefalexin 500 mg three times daily for 7 days
Number of subjects: 95
Study 8568534 — intervention group
Group type: EXPERIMENTAL
Intervention: Quantitative spasticity measures (H-reflex testing with and without Achilles tendon vibration, H-reflex testing with and without dorsiflexor contraction, reflex threshold angle, timed toe tapping)
Number of subjects: 34
Study 8568534 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified Ashworth Scale (MAS)
Number of subjects: 34
Study 8568534 — intervention group
Group type: EXPERIMENTAL
Intervention: Timed Toe Tapping (TTT)
Number of subjects: 34
Study 2146967 — intervention group
Group type: EXPERIMENTAL
Intervention: Filtered coffee
Number of subjects: 176
Study 2146967 — intervention group
Group type: EXPERIMENTAL
Intervention: Boiled coffee
Number of subjects: 176
Study 2146967 — intervention group
Group type: COMPARATOR
Intervention: No coffee (control group)
Number of subjects: 176
Study 2146967 — intervention group
Group type: EXPERIMENTAL
Intervention: Caffeine (75 mg tablets)
Number of subjects: 176
Study 2146967 — intervention group
Group type: COMPARATOR
Intervention: Placebo (control group)
Number of subjects: 176
Study 625519 — intervention group
Group type: EXPERIMENTAL
Intervention: 400 Hz pips designated as targets
Number of subjects: 12
Study 625519 — intervention group
Group type: EXPERIMENTAL
Intervention: 1600 Hz pips designated as targets
Number of subjects: 12
Study 31792921 — intervention group
Group type: EXPERIMENTAL
Intervention: Givosiran 2.5 mg/kg, administered subcutaneously monthly
Number of subjects: 0
Study 31792921 — intervention group
Group type: EXPERIMENTAL
Intervention: Givosiran
Number of subjects: 0
Study 30979401 — intervention group
Group type: EXPERIMENTAL
Intervention: Educational program followed by a structured multidisciplinary care program for management of neuropsychiatric symptoms.
Number of subjects: 305
Study 30979401 — intervention group
Group type: COMPARATOR
Intervention: Registered nurses compared to other nursing staff.
Number of subjects: 305
Study 28029329 — intervention group
Group type: EXPERIMENTAL
Intervention: Tinzaparin 175 IU/kg once daily
Number of subjects: 900
Study 28029329 — intervention group
Group type: COMPARATOR
Intervention: Dose-adjusted warfarin for 6 months
Number of subjects: 900
Study 28029329 — intervention group
Group type: EXPERIMENTAL
Intervention: TF levels
Number of subjects: 900
Study 28029329 — intervention group
Group type: EXPERIMENTAL
Intervention: Venous compression from mass
Number of subjects: 900
Study 28029329 — intervention group
Group type: EXPERIMENTAL
Intervention: Hepatobiliary cancer
Number of subjects: 900
Study 25522664 — intervention group
Group type: EXPERIMENTAL
Intervention: Perinatal Dyadic Psychotherapy (PDP)
Number of subjects: 42
Study 25522664 — intervention group
Group type: COMPARATOR
Intervention: Usual care plus depression monitoring by phone
Number of subjects: 42
Study 23360084 — intervention group
Group type: EXPERIMENTAL
Intervention: Ondansetron (8 mg i.v.)
Number of subjects: 19
Study 23360084 — intervention group
Group type: COMPARATOR
Intervention: NaCl (0.9% w/v)
Number of subjects: 19
Study 20878173 — intervention group
Group type: EXPERIMENTAL
Intervention: Minilaparotomy
Number of subjects: 205
Study 20878173 — intervention group
Group type: COMPARATOR
Intervention: Midline incision (Control)
Number of subjects: 205
Study 19436951 — intervention group
Group type: EXPERIMENTAL
Intervention: Open-door (OD) laminoplasty with unilateral mini-plating
Number of subjects: 13
Study 19436951 — intervention group
Group type: COMPARATOR
Intervention: Bilateral cutting (BL) technique with retropositioning of the laminae and bilateral mini-plating
Number of subjects: 13
Study 16889854 — intervention group
Group type: EXPERIMENTAL
Intervention: Atorvastatin 80 mg
Number of subjects: 10
Study 16889854 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study 15832067 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-hypnosis (mean of 2.4 sessions, SD 1.7; range 2-5 sessions) along with standard anti-allergic pharmacological treatment
Number of subjects: 79
Study 15832067 — intervention group
Group type: COMPARATOR
Intervention: Control group (self-hypnosis learned in year 2)
Number of subjects: 79
Study 15832067 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-hypnosis
Number of subjects: 79
Study 11981150 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous clonidine (group C)
Number of subjects: 68
Study 11981150 — intervention group
Group type: COMPARATOR
Intervention: Placebo (group P)
Number of subjects: 68
Study 9787687 — intervention group
Group type: EXPERIMENTAL
Intervention: Zidovudine/Lamivudine (ZDV/3TC)
Number of subjects: 471
Study 9787687 — intervention group
Group type: EXPERIMENTAL
Intervention: Zidovudine/Didanosine (ZDV/ddI)
Number of subjects: 471
Study 9787687 — intervention group
Group type: COMPARATOR
Intervention: Didanosine (ddI)
Number of subjects: 471
Study 7621059 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose continuous nebulization of albuterol (7.5 mg/h)
Number of subjects: 22
Study 7621059 — intervention group
Group type: COMPARATOR
Intervention: High-dose intermittent nebulization of albuterol (2.5 mg every 20 minutes for four hours)
Number of subjects: 22
Study 2534912 — intervention group
Group type: EXPERIMENTAL
Intervention: Sizofiran (Schizophyllan: SPG)
Number of subjects: 0
Study 2534912 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 0
Study 28096 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 mg clobazam
Number of subjects: 0
Study 28096 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 mg clobazam
Number of subjects: 0
Study 28096 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 29209859 — intervention group
Group type: EXPERIMENTAL
Intervention: Spicae aetheroleum (Spicae ae.)
Number of subjects: 258
Study 29209859 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 258
Study 30372756 — intervention group
Group type: EXPERIMENTAL
Intervention: Panretinal photocoagulation (PRP)
Number of subjects: 40
Study 30372756 — intervention group
Group type: COMPARATOR
Intervention: Intravitreal aflibercept
Number of subjects: 40
Study 26727655 — intervention group
Group type: EXPERIMENTAL
Intervention: Tocilizumab IV 8 mg/kg every 4 weeks over 31 min
Number of subjects: 47
Study 26727655 — intervention group
Group type: COMPARATOR
Intervention: Standard 60-min infusions of Tocilizumab IV 8 mg/kg every 4 weeks
Number of subjects: 47
Study 24184245 — intervention group
Group type: EXPERIMENTAL
Intervention: HFpEF patients
Number of subjects: 219
Study 24184245 — intervention group
Group type: COMPARATOR
Intervention: Normal controls
Number of subjects: 219
Study 24184245 — intervention group
Group type: COMPARATOR
Intervention: Hypertensive heart disease patients
Number of subjects: 219
Study 22507330 — intervention group
Group type: EXPERIMENTAL
Intervention: Allergen exposure
Number of subjects: 10
Study 22507330 — intervention group
Group type: COMPARATOR
Intervention: Diluent exposure
Number of subjects: 10
Study 19850848 — intervention group
Group type: COMPARATOR
Intervention: Timolol
Number of subjects: 140
Study 19850848 — intervention group
Group type: COMPARATOR
Intervention: Dorzolamide
Number of subjects: 140
Study 18047457 — intervention group
Group type: EXPERIMENTAL
Intervention: Progressive resistance exercise program (6 exercises, 3 times per week for 12 weeks, with increasing resistance)
Number of subjects: 54
Study 18047457 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 54
Study 15612979 — intervention group
Group type: EXPERIMENTAL
Intervention: SRL-ST (sirolimus-steroid regimen without cyclosporine)
Number of subjects: 430
Study 15612979 — intervention group
Group type: COMPARATOR
Intervention: SRL-CsA-ST (sirolimus-cyclosporine-steroid regimen)
Number of subjects: 430
Study 12211647 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin supplementation (folic acid 5 mg, pyridoxine 40 mg, cyanocobalamin 1 mg once daily)
Number of subjects: 21
Study 12211647 — intervention group
Group type: COMPARATOR
Intervention: Control group (no vitamin supplementation)
Number of subjects: 21
Study 12211647 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin supplementation
Number of subjects: 21
Study 10798173 — intervention group
Group type: EXPERIMENTAL
Intervention: Care provided in the admitting and emergency unit
Number of subjects: 100
Study 10798173 — intervention group
Group type: EXPERIMENTAL
Intervention: Care for patients with social problems
Number of subjects: 100
Study 10798173 — intervention group
Group type: EXPERIMENTAL
Intervention: Care for patients with acute problems
Number of subjects: 100
Study 10798173 — intervention group
Group type: EXPERIMENTAL
Intervention: Placement in specialty services
Number of subjects: 100
Study 10798173 — intervention group
Group type: EXPERIMENTAL
Intervention: Lack of beds
Number of subjects: 100
Study 7595106 — intervention group
Group type: EXPERIMENTAL
Intervention: Nonoperative treatment including manipulation
Number of subjects: 59
Study 1968178 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-inflation of the cuff
Number of subjects: 17
Study 1968178 — intervention group
Group type: COMPARATOR
Intervention: Wearing the inflated cuff
Number of subjects: 17
Study 1968178 — intervention group
Group type: EXPERIMENTAL
Intervention: Cuff inflation
Number of subjects: 17
Study 98802 — intervention group
Group type: EXPERIMENTAL
Intervention: Cigarettes of different lengths (whole, half, quarter, eighth)
Number of subjects: 0
Study 98802 — intervention group
Group type: EXPERIMENTAL
Intervention: Cigarettes delivering 0.2 mg nicotine/cigarette
Number of subjects: 0
Study 98802 — intervention group
Group type: EXPERIMENTAL
Intervention: Cigarettes delivering 2.0 mg nicotine/cigarette
Number of subjects: 0
Study 98802 — intervention group
Group type: EXPERIMENTAL
Intervention: Quarter length cigarettes
Number of subjects: 0
Study 28538605 — intervention group
Group type: EXPERIMENTAL
Intervention: HEADS-ED tool
Number of subjects: 639
Study 28538605 — intervention group
Group type: EXPERIMENTAL
Intervention: HEADS-ED score >= 8 and suicidality of 2
Number of subjects: 639
Study 28538605 — intervention group
Group type: EXPERIMENTAL
Intervention: Agreement on needs requiring action
Number of subjects: 639
Study 31162549 — intervention group
Group type: EXPERIMENTAL
Intervention: Dapagliflozin 10 mg
Number of subjects: 40
Study 31162549 — intervention group
Group type: COMPARATOR
Intervention: Hydrochlorothiazide (HCT) 12.5 mg
Number of subjects: 40
Study 25385202 — intervention group
Group type: EXPERIMENTAL
Intervention: Event-based interview
Number of subjects: 1728
Study 25385202 — intervention group
Group type: EXPERIMENTAL
Intervention: Frequency-based interview
Number of subjects: 1728
Study 25385202 — intervention group
Group type: COMPARATOR
Intervention: No interview
Number of subjects: 1728
Study 25385202 — intervention group
Group type: EXPERIMENTAL
Intervention: Evidence-based risk-reduction session
Number of subjects: 1728
Study 25385202 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard of care risk-reduction session
Number of subjects: 1728
Study 24369076 — intervention group
Group type: EXPERIMENTAL
Intervention: Arthroscopic partial meniscectomy
Number of subjects: 146
Study 24369076 — intervention group
Group type: COMPARATOR
Intervention: Sham surgery
Number of subjects: 146
Study 21795443 — intervention group
Group type: EXPERIMENTAL
Intervention: BOLUS (25-g dose of whey protein)
Number of subjects: 8
Study 21795443 — intervention group
Group type: COMPARATOR
Intervention: PULSE (ten 2.5-g drinks every 20 min of whey protein)
Number of subjects: 8
Study 19855332 — intervention group
Group type: EXPERIMENTAL
Intervention: Whole body vibration at 50 Hz
Number of subjects: 16
Study 19855332 — intervention group
Group type: COMPARATOR
Intervention: Whole body vibration at 20 Hz
Number of subjects: 16
Study 19855332 — intervention group
Group type: COMPARATOR
Intervention: Whole body vibration at 35 Hz
Number of subjects: 16
Study 19855332 — intervention group
Group type: COMPARATOR
Intervention: Control (no vibration)
Number of subjects: 16
Study 16942827 — intervention group
Group type: EXPERIMENTAL
Intervention: Combitube
Number of subjects: 26
Study 16942827 — intervention group
Group type: EXPERIMENTAL
Intervention: EasyTube
Number of subjects: 26
Study 16942827 — intervention group
Group type: COMPARATOR
Intervention: Tracheal intubation
Number of subjects: 26
Study 12760903 — intervention group
Group type: EXPERIMENTAL
Intervention: Duodenal infusion of 0.1 N hydrochloric acid
Number of subjects: 12
Study 12760903 — intervention group
Group type: COMPARATOR
Intervention: Duodenal infusion of saline
Number of subjects: 12
Study 11759464 — intervention group
Group type: EXPERIMENTAL
Intervention: Invitation and offer of payment for contact
Number of subjects: 200
Study 11759464 — intervention group
Group type: COMPARATOR
Intervention: No invitation and offer of payment for contact
Number of subjects: 200
Study 11759464 — intervention group
Group type: EXPERIMENTAL
Intervention: Discharge summary distribution
Number of subjects: 200
Study 11759464 — intervention group
Group type: EXPERIMENTAL
Intervention: General practitioners' contact with hospitals
Number of subjects: 200
Study 9284426 — intervention group
Group type: EXPERIMENTAL
Intervention: Losartan
Number of subjects: 0
Study 9284426 — intervention group
Group type: EXPERIMENTAL
Intervention: Candesartan cilexetil
Number of subjects: 0
Study 9284426 — intervention group
Group type: COMPARATOR
Intervention: Enalapril
Number of subjects: 0